Ophthalmology

Mental Health Scores Decreased in Patients Who Developed POAG

June 18th 2025

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists across multiple studies.

Glaucoma in older individual | Image credit: Africa Studio - stock.adobe.com

Corneal Curvature Measurements Significantly Affected by Dry Eye

June 11th 2025

Eye | Image credit: mik_cz - stock.adobe.com

Punctal Plugs Effective, Safe in Treating Moderate, Severe Dry Eye Disease

June 3rd 2025

Dry eye | Image credit: Dragana Gordic - stock.adobe.com

Lower Odds of Cataract Associated With Antioxidant Index

May 28th 2025

Cataracts | Image credit: Africa Studio - stock.adobe.com

May 14th 2025

Continuing Medical Education

View All

Integrating Multi-Cancer Early Detection Tests Into Clinical Practice: The Health Economics Perspective for Managed Care Professionals

1.5 Credits / Oncology

1 Credit / Cardiology, Neurology

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1.5 Credits / Endocrinology, Diabetes & Metabolism, Ophthalmology/Optometry

The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Ophthalmology/Optometry

Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Managed Care

1.5 Credits / Ophthalmology/Optometry

Advancing Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Optimizing Outcomes With Emerging Therapies

More News

June 26th 2023

Prevalence of Eye Disease Related to Diabetes Remains High in United States

A new study estimated that 9.60 million people are living with diabetic retinopathy and 1.84 million people are living with vision-threatening diabetic retinopathy in the United States.

June 26th 2023

Dr Byron Lam Highlights Treatments in the Pipeline for Inherited Retinal Disease

Gene therapy is only one exciting area of treatments in the pipeline to potentially treat inherited retinal disease, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.

June 19th 2023

Microbial Keratitis Severity Associated With Patient Characteristics, Location

Social risk factors, such as patient characteristics and where they live, informed the severity of microbial keratitis in a sample of patients.

June 13th 2023

Artificial Intelligence Has Potential to Estimate BCVA in Patients With DME

Fundus photographs of eyes with diabetic macular edema (DME) could be used to estimate best-corrected visual acuity (BCVA) when artificial intelligence examines the pictures.

June 11th 2023

Dr Byron Lam Reviews Current Treatments and Therapies in the Pipeline for Inherited Retinal Disease

The most exciting treatment for inherited retinal disease was approved in 2017, but there are many novel treatments in phase 2 or phase 3 trials at this point, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.

June 9th 2023

Low-dose Atropine for Pediatric Myopia Progression Found Effective in Phase 3 Trial

Childhood myopia progression could be treated with low-dose atropine due to the safety and efficacy displayed in this study.

May 30th 2023

Infliximab, Adalimumab Have Similar Efficacy in Patients With Noninfectious Uveitis

Adalimumab had a slight advantage over infliximab in terms of adverse events when used to treat patients with noninfectious uveitis (NIU).

May 29th 2023

Dr Byron Lam Discusses Impact on SES Factors on Glaucoma Screening Follow-up

Insurance is by far the most important factor of whether patients followed up with treatment after getting screened for glaucoma, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.

May 23rd 2023

Failure to Attend Follow-up Is the Main Reason for Discontinuation of Amblyopia Therapy

About 69% of pediatric patients had discontinued amblyopia therapy during COVID-19 even as their parents reported that adherence was good.

May 21st 2023

Dr Charles Wykoff: Gene Therapy for Wet AMD Would Be a Tremendous Opportunity

Gene therapies like RGX-314 are looking to treat very common diseases in ophthalmology, which would represent a tremendous opportunity for chronic disease management, said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.

May 16th 2023

Bevacizumab First-line Treatment More Cost-effective in RVO vs Aflibercept

Aflibercept was a less cost-effective treatment for retinal vein occlusion (RVO) compared with bevacizumab, although visual acuity outcomes were similar.

May 15th 2023

Dr Jennifer Sun Discusses the Importance of Diversity in Trials to Identify Biomarkers for Diabetic Eye Disease

There is a concerted effort to identify biomarkers to understand the risk of progression of diabetic eye disease, but many studies have not been performed in diverse populations, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.

May 9th 2023

Myopia Associated With Increased Risk of POAG

The relationship between myopia and primary open-angle glaucoma (POAG) was stronger in Asian, Black, and Hispanic individuals compared with White individuals.

May 3rd 2023

AI Cannot Assist in Prepping for Ophthalmology Board Certification Exams, Study Finds

When presented with a set of multiple choice questions used to help trainees practice for the ophthalmology board certification exams, the artificial intelligence (AI) chatbot ChatGPT was able to answer only half correctly.

May 1st 2023

Dr Jennifer Sun Highlights Ongoing Research on Preventive Strategies for Diabetic Eye Disease

The DRCR Retina Network is undertaking research to develop preventive strategies for diabetic eye disease, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.

April 26th 2023

Average Acuity-Based Outcomes Improved With Eyeglasses Using 0.05D Steps

Researchers found that eyeglasses with traditional steps of 0.25D were less effective and less preferred by participants compared with those refracted in 0.05D steps.

April 23rd 2023

Dr Charles Wykoff Discusses Gene Therapy to Treat Wet Age-Related Macular Degeneration

Gene therapy has the promise of being one and done, but it isn’t always that way for all patients, which leaves questions about where these therapies fit in the commercial landscape, said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.

April 17th 2023

ROP Incidence Increased in Premature Infants

Retinopathy of prematurity (ROP) was found to have increased from 2003 to 2019, especially in Black and Hispanic children.

April 17th 2023

Dr Darius Moshfeghi Outlines the Impact of Delayed Treatment in ROP

Retinopathy of prematurity (ROP) that occurs in preterm babies can progress fast, which requires quick decisions early about treatment, explained Darius M. Moshfeghi, MD, chief, Retina Division, and professor at the Horngren Family Vitreoretinal Center, Byers Eye Institute, Department of Ophthalmology, Stanford University School of Medicine.

April 12th 2023

Perfluorohexyloctane Reduced Signs and Symptoms of Dry Eye Disease

Perfluorohexyloctane (NOV03) was able to reduce the signs and symptoms of dry eye disease (DED) when compared with hypotonic saline control and was well tolerated.

April 10th 2023

Dr Charles Wykoff: Some Patients May Need Both Gene Therapy and Anti-VEGF to Treat Wet AMD

While there are benefits of gene therapy, some patients will continue to need anti–vascular endothelial growth factor (VEGF) therapy to treat wet age-related macular degeneration (AMD), said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.

April 3rd 2023

First-year Single Eye Treatment Cost Lowest With Bevacizumab for AMD, DME

Treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME) for a single year was found to be lowest when using bevacizumab.

April 3rd 2023

Switching From Aflibercept to Bevacizumab Results in Cost Savings Without Sacrificing Visual Acuity, Says Dr Jennifer Sun

The Protocol AC study analyzed visual acuity gains and cost if patients with diabetic macular edema started on bevacizumab, which costs less, and switched to aflibercept later, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.

March 30th 2023

Trajectory of Treatment Landscape for Wet AMD and DME

In their closing thoughts, the expert panelists discuss the future of the disease state and treatment options, and how they expect provider, patient, and payer value perception to change in the future.

March 30th 2023

Payer Engagement With the Retina Community

The panelists discuss how payers can best engage with the retinal disease community on a provider and patient level.

Screenshot of Eleonora Lad, MD, PhD, smiling

March 26th 2023

Dr Eleonora Lad: Early Intervention for Geographic Atrophy Prevents Too Much Irreversible Damage

The first FDA-approved therapy for geographic atrophy, pegcetacoplan, slows disease progression but does not reverse it, which means providers need to intervene early before there is too much irreversible damage, explained Eleonora Lad, MD, PhD, associate professor of ophthalmology, Duke University.

March 23rd 2023

Evolution of Access to Treatment for Wet AMD/DME Therapies

Dr Sheth discusses the evolution of access to treatment for AMD/DME over the past few years and initiatives to expand treatment access.

March 23rd 2023

Wet AMD Resource Utilization Impacted by Medication Duration of Action

Joseph Coney, MD, FASRS, FACS, discusses switching anti-VEGF agents in the treatment of wet AMD and what payers should consider when switching anti-VEGF therapies.

March 21st 2023

Estimates of Diabetic Retinopathy Incidence, Progression Lower Than Previously Reported in American Indians